| 货号 | HCA213P |
| 克隆号 | AbD17841_hIgG1 |
| 同种亚型 | IgG1 |
| 来源宿主 | HuCAL |
| 应用 | E |
| 供应商 | Bio-Rad Antibodies |
| 运输条件 | |
| 存放说明 | Store at -70oC. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.Store at +4oC or at -20oC if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
HCA213 Specificity ELISA To confirm antibody specificity, a microtiter plate was coated overnight with various antigens at a concentration of 5µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated HCA213 at 2µg/ml followed by QuantaBlu™ fluorogenic peroxidase substrate | |
Infliximab does not bind to HCA213 in the presence of TNF-α To assess the ability of HCA213 to inhibit the binding of Infliximab to its target molecule, a microtiter plate was coated overnight with HCA213 (the monovalent Fab fragment of HCA213 was used) at 5µg/ml. After washing and blocking with 5% BSA in PBST, Infliximab alone (green triangles), with 0.5 fold molar excess of TNF-α (red circles) or with 5.0 fold molar excess of TNF-α (black squares) was added in the given concentrations. Free Infliximab, still capable of binding to the plate, was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P) | |
Infliximab Inhibition ELISA To assess the ability of HCA213 to inhibit the binding of Infliximab to its target molecule, a microtiter plate was coated overnight with TNF-α at a concentration of 1µg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of HCA213 (the monovalent Fab fragment of HCA213 was used) was titrated into a constant amount of Infliximab (IFX, 0.3µg/ml). Free Infliximab, still capable of binding to the plate, was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P) | |
Infliximab Bridging ELISA for Pharmacokinetic (PK) Assay Development A microtiter plate was coated overnight with HCA212 at a concentration of 1µg/ml. After washing and blocking with PBST+5% BSA, Infliximab spiked in 10% Human serum was added at the given concentrations. Detection was performed using HRP-conjugated HCA213 at 2µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fuorogenic peroxidase substrate | |
Infliximab Bridging ELISA for Pharmacokinetic (PK) Assay Development A microtiter plate was coated overnight with HCA214 at a concentration of 5µg/ml. After washing and blocking with PBST+5% BSA, Infliximab spiked in 10% Human serum was added at the given concentrations. Detection was performed using HRP-conjugated HCA213 at 2µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate | |
HCA213 Bridging ELISA for Anti-Drug Antibody (ADA) Assay Development A microtiter plate was coated over night with Infliximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5%BSA, HCA213 spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated Infliximab at 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate |
